Clene Inc
CLNN
Get informed when a big investor buys or sells
+ FollowMarket Cap$67.62M
Close$
$-1.82
131.3% downside
Current Fair Value
131.3% downsideOvervalued by 131.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $67.62 Million |
|---|---|
| Enterprise Value | $83.73 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.65 |
| Beta | 0.89 |
| Outstanding Shares | 11,644,214 |
Return
| Return on Equity | 178.20% |
|---|---|
| Return on Assets | -154.69% |
| Return on Invested Capital | -153.24% |
Valuation & Multiples
| P/E Ratio | -2.28 |
|---|---|
| PEG | -0.23 |
| Price to Sales | - |
| Price to Book Ratio | -2.91 |
| Enterprise Value to Revenue | 624.83 |
| Enterprise Value to EBIT | -3.66 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.26 |
| Debt to Equity | -1.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.50
Average shareholder expectationRevenue Estimate
$50,750
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.37
Average shareholder expectationRevenue Estimate
$61,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 22.25%▲ 3.41% |
|---|---|
| Total Invested | $10.81M▼ 4.91% |
| Investors Holding | 29▲ 1.00% |
ESG Score
No data
About Clene Inc
2,021 employeesClene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally a...